Intraventricular tissue plasminogen activator for intraventricular hemorrhage caused by an arteriovenous malformation

Kelley Keefe, Meysam Kebriaei, Andrew Gard, Arun Angelo Patil

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

The use of thrombolytics delivered through an external ventricular drain has improved outcomes in intraventricular hemorrhage, a disease with a poor prognosis; however, presence of an arteriovenous malformation is generally considered a contraindication to thrombolytic use. Due do the high mortality with the current standard of care, thrombolytics should be considered as an acceptable treatment option despite the presence of an arteriovenous malformation in certain clinical situations. We review the available literature and present an additional patient to make the case for the use of thrombolytics for intraventricular hemorrhage from an arteriovenous malformation.

Original languageEnglish (US)
Pages (from-to)526-529
Number of pages4
JournalJournal of Clinical Neuroscience
Volume21
Issue number3
DOIs
StatePublished - Mar 2014

Keywords

  • Intracranial arteriovenous malformation
  • Intracranial hemorrhage
  • Intraventricular injections
  • Thrombolytic therapy

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Intraventricular tissue plasminogen activator for intraventricular hemorrhage caused by an arteriovenous malformation'. Together they form a unique fingerprint.

  • Cite this